Manzo Pharmaceuticals, Inc.
MNZO · OTC
12/31/2015 | 12/31/2014 | 12/31/2004 | 12/31/2003 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.19 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | -64.13% | -54.68% |
| EV / EBITDA | 847.80 | -1.09 | -2.89 | -4.44 |
| Quality | ||||
| ROIC | 0.41% | 312.14% | 0.00% | 0.00% |
| Gross Margin | 39.37% | 100.00% | 0.68% | 25.17% |
| Cash Conversion Ratio | 0.27 | 0.40 | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | -91.31% | -94.33% | 1,453,241.01% | 1,442,650.02% |
| Free Cash Flow Growth | 0.00% | 0.00% | 29.96% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -29.51 | -0.18 | -2.28 | -3.18 |
| Interest Coverage | 0.02 | -0.45 | -3.50 | -4.04 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 1.56 |
| Cash Conversion Cycle | 0.00 | 0.00 | -48.43 | 164.19 |